Neurogene
NGNE
85 hedge funds and large institutions have $187M invested in Neurogene in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 8 closing their positions.
230% more call options, than puts
Call options by funds: $287K | Put options by funds: $87K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
4% more funds holding
Funds holding: 82 → 85 (+3)
0.14% less ownership
Funds ownership: 3.18% → 3.05% (-0.14%)
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
25% less capital invested
Capital invested by funds: $249M → $187M (-$61.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.65M |
| 2 |
Renaissance Technologies
New York
|
+$1.38M |
| 3 |
Millennium Management
New York
|
+$938K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$895K |
| 5 |
Two Sigma Advisers
New York
|
+$880K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.78M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$3.15M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$834K |
| 5 |
Goldman Sachs
New York
|
-$697K |
NGNE Hedge Fund Activity: Q3 2021 in Review
85 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2021, worth a combined $187M — down 25% from $249M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NGNE positions and 8 closed out — a net gain of 4 holders — while 26 added to existing stakes and 28 trimmed.
The largest buyer was Candriam SCA, adding an estimated $2.65M. The largest seller was EcoR1 Capital, cutting an estimated $11.5M.
- 85 institutional investors held Neurogene (NGNE) as of Q3 2021, up from 82 in Q2 2021.
- Funds reported $187M of Neurogene stock for Q3 2021, down 25% quarter-over-quarter.
- 12 funds opened new Neurogene positions in Q3 2021 and 8 closed out, a net change of +4 holders.
- The largest Neurogene buyer in Q3 2021 was Candriam SCA, an estimated $2.65M added.
- The largest Neurogene seller in Q3 2021 was EcoR1 Capital, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2021.